Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Hereditary Sensory and Autonomic Neuropathies 2Genital Diseases 1Endometrial Neoplasms 1Carcinoma, Hepatocellular 1Carcinoma, Endometrioid 1Breast Neoplasms 1

Interventions

Fulvestrant 4serabelisib 2sapanisertib 2ribociclib 2palbociclib 2tivozanib 1pembrolizumab 1olaparib 1exemestane 1abemaciclib 1Tamoxifen 1Secretin 1STX-478 1Radiotherapy 1Pharmaceutical Preparations 1Paclitaxel 1Nivolumab 1Metformin 1Letrozole 1Irinotecan 1Imlunestrant 1Gemcitabine 1Carboplatin 1CA-19-9 Antigen 1Anastrozole 1AZD1390 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Hereditary Sensory and Autonomic Neuropathies × sapanisertib × Clear all
NCT07558733 2026-04-30

Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer

Faeth Therapeutics

Phase 1/2 Recruiting
32 enrolled
Breast

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT06463028 2025-12-24

Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer

Faeth Therapeutics

Phase 2 Recruiting
40 enrolled
Gynecologic

Genital Diseases, Hereditary Sensory and Autonomic Neuropathies, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡